Welcome to our dedicated page for AETHLON MEDICAL SEC filings (Ticker: AEMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aethlon Medical, Inc. filings document the regulatory record of a Nevada clinical-stage medical device company developing the investigational Aethlon Hemopurifier. Form 8-K reports cover quarterly financial results furnished under Regulation FD, material agreements tied to securities purchase arrangements, warrant-related capital-structure updates, and approved changes to the company's equity incentive plan.
Proxy materials cover annual-meeting and stockholder voting matters, including governance and compensation-plan proposals. Registration statements describe securities offered for sale, share-capital terms and related offering mechanics for the company's common stock and other securities.
Aethlon Medical (Nasdaq:AEMD) filed a Form 8-K to furnish its press release announcing financial results for the quarter ended March 31, 2025. Reported under Items 2.02 and 7.01, the filing attaches the release as Exhibit 99.1 and states the information is provided under Regulation FD and not deemed “filed” for Exchange Act purposes. No detailed financial metrics, guidance, or strategic updates are included in the 8-K itself. Aside from furnishing the exhibit, the report discloses no material events likely to affect the company’s operating outlook or capital structure. Investors must review Exhibit 99.1 for the actual results.
Aethlon Medical (NASDAQ:AEMD) filed its Annual Report for the fiscal year ended March 31, 2025.
- Maintains status as a non-accelerated filer & smaller reporting company.
- Implemented a 1-for-8 reverse stock split effective June 6 2025; post-split shares outstanding total 2,585,316.
- Aggregate market value of non-affiliate shares was $6.65 million as of Sept 30 2024 (close $3.73).
- Discloses May 2024 public offering and March 2025 warrant inducement; details appear in Equity & Liquidity sections.
- No indication of being a shell company or well-known seasoned issuer; all Exchange Act filings current.
The filing provides audited FY 2025 financial statements, updated risk factors, new Cybersecurity disclosures and forward-looking statements that may affect future capital raising and regulatory pathways.